Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | pTVG-AR |
Trade Name | |
Synonyms | MVI-118 |
Drug Descriptions |
pTVG-AR (MVI-118) is a DNA vaccine encoding the ligand binding domain of the androgen receptor (AR) that stimulates immune response against AR-expressing prostate cancer cells (PMID: 23108626, PMID: 32513836). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C121777 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Degarelix + Nivolumab + pTVG-AR | Degarelix Nivolumab pTVG-AR | 0 | 1 |
Degarelix + pTVG-AR | Degarelix pTVG-AR | 0 | 1 |
Pembrolizumab + pTVG-AR + pTVG-HP plasmid DNA vaccine + Sargramostim | Pembrolizumab Sargramostim pTVG-AR pTVG-HP plasmid DNA vaccine | 0 | 1 |
pTVG-AR | pTVG-AR | 0 | 1 |